Literature DB >> 4029259

The cardiovascular effects of oxytocin in conscious male rats.

M A Petty, R E Lang, T Unger, D Ganten.   

Abstract

In conscious, chronically instrumented normotensive male Wistar rats intravenous (i.v.) administration of oxytocin (OXT) (greater than or equal to 100 ng) induced a dose-related biphasic change in mean arterial pressure (MAP). This consisted of an initial pressor effect accompanied by bradycardia and a decrease in cardiac output (CO), followed by a more prolonged fall in MAP which reached a maximum 30 min after injection and was accompanied by an increase in CO. The more specific (Thr4,Gly7]OXT analogue (0.01-10 micrograms i.v.) caused a dose-related fall in MAP and a rise in CO which reached a maximum after 15-30 min. Similarly in spontaneously hypertensive rats of the stroke prone strain (SHRSP) an initial pressor effect and delayed fall in MAP were apparent after OXT (0.1 and 10 micrograms i.v.) only the decrease in MAP being evident with the [Thr4,Gly7]OXT analogue. These responses were significantly larger than those observed in Wistar Kyoto controls. The pressor effects are therefore interpreted to be due to vasopressin receptor activation while the depressor effects appear to be oxytocin specific. In sinoaortic denervated rats, OXT (0.1 and 10 micrograms i.v.) induced an enhanced initial pressor effect with a much reduced reflex bradycardia and fall in CO. A larger and more prolonged delayed fall in MAP was apparent with both OXT and [Thr4,Gly7]OXT accompanied by a decrease in CO when compared to sham-operated controls. Intracisternally (i.c.) administered OXT (0.05-10 ng) had no effect on MAP or heart rate.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4029259     DOI: 10.1016/0014-2999(85)90497-2

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  7 in total

1.  Intranasal application of vasopressin fails to elicit changes in brain immediate early gene expression, neural activity and behavioural performance of rats.

Authors:  M Ludwig; V A Tobin; M F Callahan; E Papadaki; A Becker; M Engelmann; G Leng
Journal:  J Neuroendocrinol       Date:  2013-07       Impact factor: 3.627

2.  Rat heart: a site of oxytocin production and action.

Authors:  M Jankowski; F Hajjar; S A Kawas; S Mukaddam-Daher; G Hoffman; S M McCann; J Gutkowska
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-24       Impact factor: 11.205

3.  Oxytocin Reduces Intravesical Pressure in Anesthetized Female Rats: Action on Oxytocin Receptors of the Urinary Bladder.

Authors:  Eduardo M Cafarchio; Luiz A da Silva; Luciana C Auresco; Itatiana F Rodart; Janaina S de Souza; Bruno B Antonio; Daniel P Venancio; Laura B M Maifrino; Rui M B Maciel; Gisele Giannocco; Patrik Aronsson; Monica A Sato
Journal:  Front Physiol       Date:  2020-05-06       Impact factor: 4.566

Review 4.  Therapeutic Potential of Oxytocin in Atherosclerotic Cardiovascular Disease: Mechanisms and Signaling Pathways.

Authors:  Ping Wang; Stephani C Wang; Haipeng Yang; Chunmei Lv; Shuwei Jia; Xiaoyu Liu; Xiaoran Wang; Dexin Meng; Danian Qin; Hui Zhu; Yu-Feng Wang
Journal:  Front Neurosci       Date:  2019-05-21       Impact factor: 4.677

Review 5.  Cardiovascular protective properties of oxytocin against COVID-19.

Authors:  Stephani C Wang; Yu-Feng Wang
Journal:  Life Sci       Date:  2021-01-26       Impact factor: 6.780

6.  A role for autonomic cardiac control in the effects of oxytocin on social behavior and psychiatric illness.

Authors:  Daniel S Quintana; Andrew H Kemp; Gail A Alvares; Adam J Guastella
Journal:  Front Neurosci       Date:  2013-04-02       Impact factor: 4.677

7.  Oxytocin's anti-inflammatory and proimmune functions in COVID-19: a transcriptomic signature-based approach.

Authors:  Ali S Imami; Sinead M O'Donovan; Justin F Creeden; Xiaojun Wu; Hunter Eby; Cheryl B McCullumsmith; Kerstin Uvnäs-Moberg; Robert E McCullumsmith; Elissar Andari
Journal:  Physiol Genomics       Date:  2020-08-18       Impact factor: 3.107

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.